CA2441099C - Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases - Google Patents

Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases Download PDF

Info

Publication number
CA2441099C
CA2441099C CA2441099A CA2441099A CA2441099C CA 2441099 C CA2441099 C CA 2441099C CA 2441099 A CA2441099 A CA 2441099A CA 2441099 A CA2441099 A CA 2441099A CA 2441099 C CA2441099 C CA 2441099C
Authority
CA
Canada
Prior art keywords
epicatechin
amyloid
amyloidosis
disease
synuclein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2441099A
Other languages
English (en)
French (fr)
Other versions
CA2441099A1 (en
Inventor
Alan D. Snow
Gerardo M. Castillo
Paula Y. Choi
Beth P. Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognitive Clarity Inc
Original Assignee
ProteoTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/938,987 external-priority patent/US6607758B2/en
Priority claimed from PCT/US2001/051131 external-priority patent/WO2002042429A2/en
Application filed by ProteoTech Inc filed Critical ProteoTech Inc
Publication of CA2441099A1 publication Critical patent/CA2441099A1/en
Application granted granted Critical
Publication of CA2441099C publication Critical patent/CA2441099C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2441099A 2001-03-15 2002-02-15 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases Expired - Fee Related CA2441099C (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US27686601P 2001-03-15 2001-03-15
US60/276,866 2001-03-15
US09/938,987 2001-08-24
US09/938,987 US6607758B2 (en) 1997-05-15 2001-08-24 Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
WOPCT/US01/51131 2001-11-02
US10/053,625 2001-11-02
PCT/US2001/051131 WO2002042429A2 (en) 2000-11-03 2001-11-02 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
US10/053,625 US6929808B2 (en) 2000-11-03 2001-11-02 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
US33872101P 2001-12-04 2001-12-04
US60/338,721 2001-12-04
US33896901P 2001-12-10 2001-12-10
US33903301P 2001-12-10 2001-12-10
US60/338,969 2001-12-10
US60/339,033 2001-12-10
PCT/US2002/004764 WO2002076381A2 (en) 2001-03-15 2002-02-15 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases

Publications (2)

Publication Number Publication Date
CA2441099A1 CA2441099A1 (en) 2002-10-03
CA2441099C true CA2441099C (en) 2011-04-19

Family

ID=56290250

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2441099A Expired - Fee Related CA2441099C (en) 2001-03-15 2002-02-15 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases

Country Status (6)

Country Link
EP (1) EP1377287A4 (enExample)
JP (1) JP4380991B2 (enExample)
AU (1) AU2002250117B2 (enExample)
CA (1) CA2441099C (enExample)
NZ (1) NZ528322A (enExample)
WO (1) WO2002076381A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
CA2499549C (en) * 2002-10-11 2012-01-24 Proteotech, Inc. Isolation, purification and synthesis of procyanidin b2 and uses thereof
JP2006232670A (ja) * 2003-05-20 2006-09-07 Ajinomoto Co Inc 神経障害用薬剤
WO2005082351A1 (ja) * 2004-03-02 2005-09-09 Eisai R & D Management Co., Ltd. 神経変性疾患治療剤
DK2004155T3 (en) * 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
WO2009104556A1 (ja) * 2008-02-19 2009-08-27 株式会社岐阜セラツク製造所 組成物
JP5738755B2 (ja) * 2008-05-09 2015-06-24 アイカーン スクール オブ メディシン アット マウント シナイ 神経変性疾患を予防および治療するための方法
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
CN107530385A (zh) 2015-05-11 2018-01-02 株式会社明治 用于促进脑源性神经营养因子产生的组合物
KR102441381B1 (ko) * 2016-07-18 2022-09-07 (주)아모레퍼시픽 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물
WO2021193703A1 (ja) * 2020-03-24 2021-09-30 学校法人 芝浦工業大学 中枢神経賦活組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US6346280B1 (en) * 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
CA2322860C (en) * 1998-03-12 2010-10-19 Mars, Incorporated Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
AU3886200A (en) * 1999-03-15 2000-10-16 Proteotech, Inc. Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
EP1246632A4 (en) * 1999-12-30 2004-08-18 Proteotech Inc CATECHINE AND GREEN TEA EXTRACT FOR TREATING AMYLOIDOSES IN GENERAL OR. AT ALZHEIMER

Also Published As

Publication number Publication date
CA2441099A1 (en) 2002-10-03
JP4380991B2 (ja) 2009-12-09
EP1377287A2 (en) 2004-01-07
WO2002076381A3 (en) 2002-11-21
WO2002076381A2 (en) 2002-10-03
AU2002250117B8 (en) 2002-10-08
AU2002250117B2 (en) 2007-11-29
EP1377287A4 (en) 2007-11-14
JP2005505497A (ja) 2005-02-24
NZ528322A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
US20100010079A1 (en) Proanthocyanidins for the Treatment of Amyloid and Alpha-Synuclein Diseases
US9133176B2 (en) Isolation, purification and synthesis of procyanidin B2 and uses thereof
US6929808B2 (en) Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
Snow et al. The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles
CA2289531C (en) Composition and methods for treating alzheimer's disease and other amyloidoses
AU2002239764A1 (en) Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
US6264994B1 (en) Compositions for treating alzheimer's disease and other amyloidoses
AU2002250117B2 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
US6346280B1 (en) Composition and methods for inhibiting the formation of brain amyloid deposits
AU2002250117A1 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
EP4058040B1 (en) Composition for reducing cardiovascular risk
US20100197778A1 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
EP1921076A1 (en) systhesis of procyanidin B2
Kastin et al. the Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200217